{"id":"pathogen-reduced-plasma","safety":{"commonSideEffects":[{"rate":null,"effect":"Transfusion-related acute lung injury (TRALI)"},{"rate":null,"effect":"Allergic reaction"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Circulatory overload"}]},"_chembl":{"chemblId":"CHEMBL2108772","moleculeType":"Unknown"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The product uses solvent/detergent or photochemical treatment methods to inactivate enveloped and non-enveloped viruses, bacteria, and other pathogens present in donated plasma. This reduces transfusion-transmitted infection risk while maintaining the coagulation factors and other plasma proteins needed for hemostasis and volume replacement.","oneSentence":"Pathogen-reduced plasma is human blood plasma treated with a pathogen reduction technology to inactivate or remove infectious agents while preserving hemostatic function.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:59:50.914Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Coagulation factor replacement in patients requiring plasma transfusion"},{"name":"Volume expansion and hemostatic support in acute bleeding or surgical settings"}]},"trialDetails":[{"nctId":"NCT07270523","phase":"NA","title":"Therapeutic Monitoring of Beta-lactams in Critically Ill Patients With Sepsis","status":"NOT_YET_RECRUITING","sponsor":"Complexo Hospitalario Universitario de A Coruña","startDate":"2026-01-01","conditions":"Bacterial Sepsis","enrollment":198},{"nctId":"NCT07265843","phase":"PHASE4","title":"Fibrinogen in Liver Transplant","status":"NOT_YET_RECRUITING","sponsor":"Trauma Hemostatis and Oxygenation Research (THOR) Network","startDate":"2026-01-01","conditions":"Liver Transplant Surgery","enrollment":60},{"nctId":"NCT06764927","phase":"PHASE4","title":"Fibrinogen in Liver Transplant Subjects","status":"NOT_YET_RECRUITING","sponsor":"Ezeldeen Abuelkasem","startDate":"2025-10-31","conditions":"Liver Transplant Surgery","enrollment":30},{"nctId":"NCT04681638","phase":"PHASE4","title":"Plasma Resuscitation Without Lung Injury","status":"TERMINATED","sponsor":"Coalition for National Trauma Research","startDate":"2022-08-17","conditions":"Burns","enrollment":13},{"nctId":"NCT04345523","phase":"PHASE2","title":"Convalescent Plasma Therapy vs. SOC for the Treatment of COVID-19 in Hospitalized Patients","status":"COMPLETED","sponsor":"Cristina Avendaño Solá","startDate":"2020-04-03","conditions":"COVID-19","enrollment":350},{"nctId":"NCT04345991","phase":"PHASE2","title":"Efficacy of Convalescent Plasma to Treat COVID-19 Patients, a Nested Trial in the CORIMUNO-19 Cohort","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2020-04-15","conditions":"Covid19","enrollment":120},{"nctId":"NCT04362176","phase":"PHASE3","title":"Passive Immunity Trial for Our Nation to Treat COVID-19 in Hospitalized Adults","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2020-04-24","conditions":"COVID-19, Coronavirus, SARS-CoV-2","enrollment":974},{"nctId":"NCT04374565","phase":"PHASE2","title":"Convalescent Plasma for Treatment of COVID-19 Patients With Pneumonia","status":"COMPLETED","sponsor":"University of Virginia","startDate":"2020-05-05","conditions":"Corona Virus Infection, SARS-CoV 2, SARS Pneumonia","enrollment":29},{"nctId":"NCT02964325","phase":"NA","title":"Efficacy of Mirasol-treated Apheresis Platelets in Patients With Hypoproliferative Thrombocytopenia","status":"TERMINATED","sponsor":"Terumo BCTbio","startDate":"2017-05-05","conditions":"Hematologic Malignancies, Hypoproliferative Thrombocytopenia","enrollment":422},{"nctId":"NCT04389944","phase":"NA","title":"Amotosalen-Ultraviolet A Pathogen-Inactivated Convalescent Plasma in Addition to Best Supportive Care and Antiviral Therapy on Clinical Deterioration in Adults Presenting With Moderate to Severe COVID-19","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2020-03-31","conditions":"Coronavirus Disease 2019 Infectious Disease (COVID-19 Infection)","enrollment":15},{"nctId":"NCT01789762","phase":"PHASE4","title":"Evaluation of the Efficacy of Platelets Treated With Pathogen Reduction Process","status":"COMPLETED","sponsor":"Etablissement Français du Sang","startDate":"2013-05","conditions":"Aplasia With Expected Thrombocytopenia","enrollment":842},{"nctId":"NCT02305732","phase":"","title":"A Prospective, Open Label, Treatment Use Study of Patient Safety Following Transfusion of INTERCEPT Platelet Components","status":"COMPLETED","sponsor":"Cerus Corporation","startDate":"2015-03","conditions":"Chikungunya Virus, Dengue Virus","enrollment":90},{"nctId":"NCT02783313","phase":"NA","title":"Pathogen Reduction Evaluation & Predictive Analytical Rating Score","status":"COMPLETED","sponsor":"Sanquin Research & Blood Bank Divisions","startDate":"2010-11-17","conditions":"Thrombocytopenia","enrollment":567},{"nctId":"NCT01368211","phase":"PHASE2, PHASE3","title":"Mirasol-Treated Platelets - (Pathogen Reduction Extended Storage Study)","status":"TERMINATED","sponsor":"Terumo BCTbio","startDate":"2010-09","conditions":"Thrombocytopenia","enrollment":16},{"nctId":"NCT02007473","phase":"","title":"A Prospective Non-interventional Study to Evaluate the Safety of Methylene Blue Plasma","status":"COMPLETED","sponsor":"Maco Productions S.A.S.","startDate":"2013-07","conditions":"Adverse Effects in the Therapeutic Use of Plasma Substitutes","enrollment":8}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["PRP"],"phase":"marketed","status":"active","brandName":"Pathogen-Reduced Plasma","genericName":"Pathogen-Reduced Plasma","companyName":"Coalition for National Trauma Research","companyId":"coalition-for-national-trauma-research","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pathogen-reduced plasma is human blood plasma treated with a pathogen reduction technology to inactivate or remove infectious agents while preserving hemostatic function. Used for Coagulation factor replacement in patients requiring plasma transfusion, Volume expansion and hemostatic support in acute bleeding or surgical settings.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}